DDrare: Database of Drug Development for Rare Diseases

Questran (DrugBank: -)

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］	1
254	ポルフィリン症	1
297	アラジール症候群	1

93. 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］　［臨床試験数：230，薬物数：215（DrugBank：51），標的遺伝子数：34，標的パスウェイ数：107］

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 230 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02963077 (ClinicalTrials.gov)	July 2013	1/11/2016	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects	Orphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome	Drug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: Placebo	Albireo	NULL	Completed	18 Years	60 Years	Both	94	Phase 1	NULL

254. ポルフィリン症　［臨床試験数：59，薬物数：52（DrugBank：17），標的遺伝子数：17，標的パスウェイ数：33］

Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 59 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-002863-28-GB (EUCTR)	26/09/2007	15/08/2007	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Erythropoietic protoporphyria (EPP) MedDRA version: 9.1;Level: LLT;Classification code 10015289;Term: Erythropoietic protoporphyria	Trade Name: Questran Product Name: Questran INN or Proposed INN: COLESTYRAMINE	Guy's & St Thomas' NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	21	Phase 4	United Kingdom

297. アラジール症候群　［臨床試験数：26，薬物数：16（DrugBank：8），標的遺伝子数：2，標的パスウェイ数：2］

Searched query = "Alagille syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 26 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02963077 (ClinicalTrials.gov)	July 2013	1/11/2016	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects	Orphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome	Drug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: Placebo	Albireo	NULL	Completed	18 Years	60 Years	Both	94	Phase 1	NULL